一段话概述
Mammoth searches for and engineers unusually small CRISPR proteins. Size is the point: the standard delivery vehicle for in vivo therapy has a strict weight limit, and a smaller editor leaves room for everything else that has to travel with it. The same proteins also power rapid diagnostic tests.
Mammoth Biosciences was founded in 2017 by Jennifer Doudna, Trevor Martin, Janice Chen and Lucas Harrington. It develops ultracompact CRISPR systems including NanoCas for in vivo editing where AAV packaging limits bind, and CRISPR-based diagnostics derived from collateral cleavage activity.
Sources
- Mammoth Biosciences
Mammoth Biosciences ↗
非投资建议
本档案为依据公开披露信息汇编的教育性资料，不构成对任何证券的买入、卖出或持有建议，也不代表对该公司前景的任何判断。生物技术领域具有高度投机性，大多数临床项目最终以失败告终。
完整免责声明 →